Pathogenic Neisseriae: Gonorrhea, Neonatal Ophthalmia and Meningococcal Meningitis (page 4)
(This chapter has 7 pages)
© 2008 Kenneth Todar, PhD
Host Defenses
Infection stimulates inflammation and a local immune (IgA) response.
Inflammation
focuses the host defenses but also becomes the pathology of the
disease.
It is not known whether the secretory immune response is protective.
Serum
antibodies also appear, and IgG and complement may be components of the
inflammatory exudate. But whether the immune defenses provide much
protection
against reinfection has not been clearly shown. In any case, immunity
is
expected to be strain specific so that reinfection may occur.
Not everyone exposed to N. gonorrhoeae acquires the disease.
This
may be due to variations in the size or virulence of the inoculum, to
natural
resistance, or to specific immunity. A 50% infective dose (ID50)
of about 1,000 bacteria has been determined based on experimental
urethral
inoculation of male volunteers. No data is available for females.
Nonspecific factors have been implicated in natural resistance to
gonococcal
infection. In women, changes in the genital pH and hormones may
increase
resistance to infection at certain times of the menstrual cycle. Urine
contains bactericidal and bacteriostatic components against N.
gonorrhoeae.
Factors in urine that may be important are pH, osmolarity, and the
concentration
of urea. The variability in the susceptibility of gonococcal strains to
the bactericidal and bacteriostatic properties of urine is thought to
be
one of the reasons some males apparently do not develop a gonorrhea
infection
when exposed.
Most uninfected individuals have serum antibodies that react with
gonococcal
antigens. These antibodies probably result from colonization or
infection
by various Gram-negative bacteria that possess cross-reactive antigens.
Such "natural antibodies" may be important in individual natural
resistance or susceptibility to infection, but this has not been
clearly
demonstrated.
Infection with N. gonorrhoeae stimulates both mucosal and
systemic
antibodies to a variety of gonococcal antigens. Mucosal antibodies are
primarily IgA and IgG. In genital secretions, antibodies have been
identified
that react with Por, Opa, Rmp and LOS. Vaccine trials have suggested
that
specific anti-fimbrial antibodies inhibit the fimbrial-mediated
attachment
of the homologous gonococcal strain. In general, the IgA response is
brief
and declines rapidly after treatment; IgG levels decline more
slowly.
Anti-Por antibodies apparently are bactericidal for the gonococcus. IgG
that reacts with Rmp blocks the bactericidal activity of antibodies
directed
against Por and LOS. Genital infection with N. gonorrhoeae
stimulates
a serum antibody response against the LOS of the infecting strain.
Disseminated
gonococcal infection results in much higher levels of anti-LOS antibody
than do genital infections.
Strains that cause uncomplicated genital infections usually are
killed
by normal human serum and are termed serum sensitive. This
bactericidal
activity is mediated by IgM and IgG antibodies that recognize sites on
the LOS. Strains that cause disseminated infections are not killed by
most
normal human serum and are referred to as serum resistant.
Resistance
is mediated, in part, by IgA that blocks the IgG-mediated
bactericidal
activity of the serum. Serum from convalescent patients with
disseminating
infections contains bactericidal IgG to the LOS of the infecting
strain.
Individuals with inherited complement deficiencies have a markedly
increased
risk of acquiring systemic neisserial infections and are subject to
recurring
episodes of systemic gonococcal and meningococcal infections,
indicating
that the complement system is important in host defense. Gonococci
activate
complement by both the classic and alternative pathways. Complement
activation
by gonococci leads to the formation of the C5b-9 complex (membrane
attack
complex) on the outer membrane. In normal human serum, similar numbers
of C5b-9 complexes are deposited on serum-sensitive and serum-resistant
organisms, but the membrane attack complex is not functional on
serum-resistant
organisms.
Treatment
The recommended treatment for uncomplicated infections is a
third-generation
cephalosporin or a fluoroquinolone plus an antibiotic (e.g.,
doxycycline
or erythromycin) effective against possible coinfection with Chlamydia
trachomatis. Sex partners should be referred and treated. The
current
CDC
Treatment Guidelines recommend treatment of all gonococcal
infections
with antibiotic regimens effective against resistant strains. The
recommended
antimicrobial agents are ceftriaxone, cefixime, ciprofloxacin, or
oflaxacin.
Control
There is no effective vaccine to prevent gonorrhea. Candidate vaccines
consisting of PilE protein or Por are of little
benefit.
The development of an effective vaccine has been hampered by the lack
of
a suitable animal model and the fact that an effective immune response
has never been demonstrated. Condoms are effective in preventing the
transmission
of gonorrhea.
The evolution of antimicrobial resistance in N. gonorrhoeae
may
ultimately affect the control of gonorrhea. Strains with multiple
chromosomal
resistance to penicillin, tetracycline, erythromycin, and cefoxitin
have
been identified in the United States and most other parts of the world.
Sporadic high-level resistance to spectinomycin and fluoroquinolones
has
been reported. Penicillinase-producing strains of N. gonorrhoeae
were first described in 1976. Five related ß-lactamase plasmids
of
different sizes have been identified. Their prevalence
penicillin-resistant
strains has increased dramatically in the United States since 1984.
Plasmid-mediated resistance of N. gonorrhoeae to
tetracycline
was first described in 1986 and has now been reported in most parts of
the world. This resistance is due to the presence of the streptococcal
tetM determinant on a gonococcal conjugative plasmid.
Tailpiece
The only natural host for N. gonorrhoeae is humans. Gonorrhea
has all but disappeared in Scandinavia and several other European
countries. However, the disease is very common in the United States.
CDC estimates that more than 700,000 persons in the U.S. get new
gonorrheal infections each year. Only about half of these infections
are reported to CDC. In 2002, 351,852 cases of gonorrhea were reported
to CDC. In the period from 1975 to 1997, the national gonorrhea rate
declined, following the implementation of the national gonorrhea
control program in the mid-1970s. After a small increase in 1998, the
gonorrhea rate has decreased slightly since 1999. In 2002, the rate of
reported gonorrheal infections was 125.0 per 100,000 persons.
Gonorrhea is transmitted almost exclusively by sexual contact. Any
sexually active person can be infected with gonorrhea. In the United
States, the highest reported rates of infection are among sexually
active teenagers, young adults, and African Americans. Persons who have
multiple sex partners are at highest risk. Rates of gonorrhea are
higher in males and in minority
and inner-city populations.
Gonorrhea is usually contracted from a sex partner who is either
asymptomatic
or has only minimal symptoms. It is estimated that the efficiency of
transmission
after one exposure is about 35 percent from an infected woman to an
uninfected
man and 50 to 60 percent from an infected man to an uninfected woman.
More
than 90 percent of men with urethral gonorrhea will develop symptoms
within
5 days; fewer than 50 percent of women with genital gonorrhea will do
so.
Women with asymptomatic infections are at higher risk of developing
pelvic
inflammatory disease and disseminated gonococcal infection.